Shares in Belgium’s UCB SA soared to a record, while rival MoonLake Immunotherapeutics lost most of its value, after the latter announced late-stage trial data for an experimental skin disease drug that analysts said failed to demonstrate superiority to one of UCB’s most important medicines.
